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Abstract
Human African trypanosomiasis (HAT) manifests in two stages of disease: firstly, haemolymphatic, and secondly, an
encephalitic phase involving the central nervous system (CNS). New drugs to treat the second-stage disease are urgently
needed, yet testing of novel drug candidates is a slow process because the established animal model relies on detecting
parasitemia in the blood as late as 180 days after treatment. To expedite compound screening, we have modified the GVR35
strain of Trypanosoma brucei brucei to express luciferase, and have monitored parasite distribution in infected mice
following treatment with trypanocidal compounds using serial, non-invasive, bioluminescence imaging. Parasites were
detected in the brains of infected mice following treatment with diminazene, a drug which cures stage 1 but not stage 2
disease. Intravital multi-photon microscopy revealed that trypanosomes enter the brain meninges as early as day 5 post-
infection but can be killed by diminazene, whereas those that cross the blood-brain barrier and enter the parenchyma by
day 21 survived treatment and later caused bloodstream recrudescence. In contrast, all bioluminescent parasites were
permanently eliminated by treatment with melarsoprol and DB829, compounds known to cure stage 2 disease. We show
that this use of imaging reduces by two thirds the time taken to assess drug efficacy and provides a dual-modal imaging
platform for monitoring trypanosome infection in different areas of the brain.
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Introduction
Human African trypanosomiasis (HAT), also known as sleeping
sickness, is endemic to sub-Saharan Africa [1,2] and is almost
always fatal if untreated. Although its prevalence fell to a position
of near control in the 1960s, a breakdown of surveillance and
treatment allowed its re-emergence, with an estimated 300,000
cases annually by 1998. Over the past decade there has again been
a steady decline in disease incidence most likely due to increased
surveillance, distribution of free drugs and implementation of
several clinical trials, but previous experience suggests that
eradication is by no means assured [3,4].
Development of a vaccine for HAT is unlikely due to the
process of antigenic variation [5,6] and the control of the tsetse fly
responsible for disease transmission is problematic [7]. Chemo-
therapy is thus fundamental to efforts to eliminate HAT [8].
However, current drugs for HAT are highly unsatisfactory; with
varying degrees of toxicity, a need for costly parenteral adminis-
tration, efficacy below 100% and resistance a growing problem
[9,10]. To address these issues, a ‘‘pipeline’’ of new compounds
has now emerged, although only two compounds (fexinidazole and
SCYX-7158) are in clinical trials with a third, CPD-0802 (DB829)
in advanced preclinical trials [8]. However, these novel drugs may
not fulfil the requirements of potency and pharmacokinetic and
safety profiles needed to eradicate the disease.
A major confounding factor in the development of new drugs
for HAT is the lack of an efficient model for the second stage of the
disease, when trypanosomes have become manifest in the central
nervous system (CNS). The current model involves infecting mice
with the GVR35 strain of Trypanosoma brucei brucei which become
established in the CNS by 21 days [11]. Candidate drugs are then
given and possible recrudescence of infection monitored in blood
samples taken over a period of 180 days. The time delay in
obtaining results is clearly a hindrance to defining structure
activity relationships in iterative rounds of chemical synthesis.
In recent years, the improved sensitivity of in vivo imaging has
expanded its application to a broad range of basic biological
questions including disease modeling and drug screening. In
infection biology, successful models to screen for drugs and
infection patterns have been established for a number of microbes
including Mycobacterium tuberculosis [12], Streptococcus pneumoniae [13],
Leishmania [14] and Trypanosoma brucei [15,16]. To determine
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whether use of in vivo imaging could yield a shortened method for
screening candidate stage two drugs, we generated transgenic
strains of brain invasive, chronically infecting T. brucei that stably
express firefly luciferase. We show here that bioluminescence
imaging of infected mice can radically shorten the period required
to assess the in vivo efficacy of candidate drugs for stage 2
trypanosomiasis.
Materials and Methods
Ethics statement
All animal experiments were performed in accordance with the
Animals (Scientific Procedures) Act 1986 and the University of
Glasgow care and maintenance guidelines. All animal protocols
and procedures were approved by The Home Office of the UK
government and the University of Glasgow Ethics Committee.
Animal infections
Adult female CD-1 mice (20–30 g body weight) were purchased
from Charles River Laboratories and maintained under specific
pathogen-free conditions. Mice were infected with 56104 Trypano-
soma brucei brucei 427 (WT, -LUC2 or –Rluc), or with 36104 T. b.
brucei strain GVR35 (WT, -LUC2 or -mCherry) trypanosomes by
intraperitoneal injection and monitored for parasitemia by
counting trypanosomes, in blood taken from the tail vein, using a
haemocytometer (sensitivity of 26104 parasites/ml).
Generation of expression constructs
To generate the backbone construct (pTbAM) that would be
used to integrate reporters into the ribosomal DNA (rDNA) loci, a
250 bp sequence corresponding to the T. b. brucei rDNA promoter
was amplified from genomic DNA using a forward primer to
introduce a SacI restriction site and a reverse primer that
introduced MluI and NotI sites (Table S1). In addition, a 563 bp
fragment of the rDNA non-transcribed spacer sequence was also
amplified from genomic DNA using a forward and reverse primer
that introduced ApaI and KpnI restriction sites. Both amplicons
were sequentially digested with SacI and NotI or ApaI and KpnI
respectively and then ligated either side of a puromycin resistance
cassette flanked by ab Tubulin intergenic regions into a pBluescript
backbone to create pTb-R. An upstream 59-untranslated region
(UTR) gene regulatory element corresponding to the T. b. brucei
GPEET2 59UTR, was amplified using primers to introduce NotI
and XhoI restriction sites. The GPEET2 59UTR amplicon and
pTb-R backbone were digested with NotI and XhoI and ligated to
create pTbAM. The enhanced firefly luciferase gene, luc2, was
amplified from pGL4.14 (Promega) using forward and reverse
primers to introduce an XhoI site before and a BamHI site after the
gene, and cloned into pGEMT. Following digestion with these
restriction enzymes the luc2 gene was cloned into the XhoI/BamHI
digested pTbAM vector to create pTbR-LUC2 (pGL2116). The
mCherry gene was amplified using primers to add HindIII and
BamHI sites and cloned into pGEMT. HindIII/BamHI digested
mCherry was cloned into pHD1034 (from C. Clayton, [17]) to
generate pHD1034-mCherry (pGL2160), and into p2628 (from
M. Carrington [18]) to generate pGL2036.
Culture-adaptation of GVR35 WT
T. brucei GVR35 WT had previously only been passaged
through mice and in order to generate a bioluminescent line the
cells had to be adapted to in vitro culture. Mice were infected with
the mouse-passaged GVR35 WT line and monitored for
parasitemia daily. During the first peak of parasitemia while
trypanosomes were still dividing, blood was harvested and added
to flasks containing different types of media and a range of fetal
calf serum concentrations at 37uC, 5% CO2. GVR35 trypano-
somes grew only in IMDM (Iscove’s Modified Dulbecco’s
Medium, Gibco) supplemented with 20% heat-inactivated fetal
calf serum (PAA), 20% Serum Plus, 0.75 mM hypoxanthine in
0.1 N NaOH, 4.1 mM glucose, 0.12 mM thymidine, 1.5 mM
sodium pyruvate, 0.037 mM bathocuproine disulphonic acid,
0.2 mM b-mercaptoethanol, 1.1 mM L-cysteine, 0.38 mM aden-
osine, 0.38 mM guanosine, 0.83 g.L21 methylcellulose, 0.04 mM
kanamycin, 75 units.ml21 penicillin and 0.075 mg.ml21 strepto-
mycin (all Sigma-Aldrich). Trypanosomes were fully adapted to
culture and growing at a constant rate of 3-fold overnight after a
month of culture. At this stage stabilates were made in
supplemented IMDM medium containing 10% glycerol and
frozen in liquid nitrogen for future use. All genetic modifications
were done on culture-adapted GVR35 WT cells within a week
after defrosting stabilates. For both WT and transgenic GVR35, in
vitro culturing was kept to a minimum to avoid effects on virulence.
T. brucei culturing and transfections
Culture-adapted Trypanosoma brucei brucei strain GVR35 blood-
stream forms were grown in vitro at 37uC, 5% CO2 in
supplemented IMDMmedium (as described in Culture-adaptation
of GVR35 WT). For generation of bioluminescent GVR35 lines
20 mg of KpnI/SacI-linearized pTbR-LUC2 plasmid was transfect-
ed into 36107 mid-log GVR35 WT trypanosomes using the
Human T-cell Solution and Amaxa Nucleofector (Lonza) set on
program X-001. GVR35-mCherry lines were generated by
transfection using NotI-linearized pHD1034-mCherry plasmid.
After recovery for 24 hours transformed clones were selected by
limiting dilution in the presence of 0.15 mg.ml21 puromycin
(Calbiochem). T. brucei Lister 427 bloodstream form cells were
grown in HMI-9 medium supplemented with 20% heat-inactivat-
ed fetal calf serum (PAA), 50 units.ml21 penicillin and 50 mg.ml21
streptomycin (Sigma) at 37uC, 5% CO2. Reporter 427 lines were
generated by transfecting 16107 mid-log 427 WT cells with 20 mg
of linearized plasmid using the Human T-cell Solution and Amaxa
Nucleofector (Lonza). NotI-digested pGL2036 plasmid was used to
Author Summary
Trypanosoma brucei, a parasite transmitted by the bite of
tsetse fly, is responsible for the disease human African
trypanosomiasis (HAT). In advanced stages of HAT,
trypanosomes invade the central nervous system (CNS),
resulting in an array of neurological symptoms, and
eventually death. Existing drugs for treatment of HAT are
highly unsatisfactory and new safe drugs are urgently
needed. Currently, potential drugs for HAT are screened in
a mouse model that relies on the emergence of trypano-
somes from tissues and their detection in blood. This can
take up to 200 days, making selection and further
development of new drugs slow and costly. Here, we
employ in vivo imaging and genetically modified trypano-
somes to monitor parasite distribution throughout the
body in live infected mice. Our bioluminescence imaging
approach provides sensitive detection of trypanosomes at
sites of infection, allowing more rapid and more effective
in vivo screening of candidate HAT drugs. Higher resolu-
tion intra-vital microscopy was used to investigate
trypanosome dynamics in the brain and their accessibility
to drugs during infection. These approaches allow more
sensitive real time tracking of trypanosomes during
chronic infections and will provide new insights about
trypanosome pathogenesis in future experiments.
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generate 427-mCherry while NotI-digested Rluc-pHD309 [15] and
KpnI/SacI-digested TbR-LUC2 was used to generate biolumines-
cent lines. After recovery for 6 hours transformed clones were
selected by limiting dilution in the presence of appropriate
antibiotics 5 mg.ml21 hygromycin B (Calbiochem) or 0.5 mg.ml21
puromycin (Calbiochem).
In vitro luciferase assay
Mid-log bloodstream form trypanosomes, grown in vitro, were
centrifuged at 1500 g for 10 minutes. Cells were resuspended in
100 ml of RPMI and added to 100 ml reconstituted luciferase assay
reagent (Promega). For the analysis of clones, bioluminescence
from 16106 cells was measured at different times after addition of
substrate using an EnVision plate reader (PerkinElmer), and
expressed as relative light units. For the in vitro detection limit
assay, bioluminescence from 10–107 cells was measured in 96-well
plates using an IVIS Spectrum (Caliper Life Sciences) and
expressed as total flux in photons per second.
In vitro drug sensitivity assays
The IC50 values for trypanocides were determined by using a
modified Alamar Blue assay. Cells were grown in IMDM medium
supplemented as described earlier and assays performed in
duplicate on three independent occasions. Briefly, mid-log strain
GVR35 WT and GVR35-LUC2 trypanosomes were added to
a dilution series of drugs in IMDM at a final density of 36104
cells/ml. After incubation for 48 hours at 37uC, 5% CO2 Alamar
Blue reagent (20 ml, 0.49 mM resazurin in PBS, pH 7.4; Sigma-
Aldrich) was added to each well and plates incubated for another
48 hours. For DB829 assays the final cell density was adjusted to
16104 cells/ml. Alamar Blue was added after 72 hours and
incubated for a further 48 hours. Fluorescence (excitation of
530 nm and emission of 590 nm) was measured using a FLUOstar
OPTIMA microplate reader (BMG LABTECH) and IC50 values
determined using GraFit5 (Erithacus Software).
In vivo drug treatments
Mice infected with strain GVR35-LUC2 were treated with
trypanocidal compounds after bioluminescence imaging from 21
days post-infection. For diminazene aceturate (Sigma-Aldrich),
mice were injected intraperitoneally with a single dose of 40 mg/
kg diluted in distilled water. Melarsoprol gel was prepared as
described previously [19] and 0.1 ml (containing 3.6 mg melar-
soprol) was applied topically to the back of the neck for 3
consecutive days. DB75 [2,5-bis(4-aminidinophenyl)furan] and
DB829 (CPD-0801, both provided by Rick Tidwell, University of
North Carolina, Chapel Hill) dissolved in DMSO were diluted in
distilled water before injecting intraperitoneally into mice. DB75
was injected at 20 mg/kg for 5 consecutive days while four
different doses of DB829 were used: 40 mg/kg for 3 days followed
by 20 mg/kg for 1 day, 25 mg/kg for 2 days followed by 40 mg/
kg for 2 days, 25 mg/kg for 5 days and 20 mg/kg for 4 days.
Bioluminescence imaging
Prior to bioluminescence imaging, mice were injected with the
relevant substrate and imaged under isoflurane anaesthesia using
an IVIS spectrum (Caliper Life Science). For LUC2, 150 mg/kg
of D-luciferin was injected intraperitoneally 10 minutes prior to
imaging while for Rluc, mice were injected intravenously
with 15 mg coelenterazine h (Caliper Rediject Coelenterazine
h) immediately before imaging. Images were acquired using 10–
60 seconds exposure and small or large binning depending on the
light produced, 1 f/stop, and an open filter. For whole body
images field of view E (25.6625.6 cm) and for head images field of
view A (464 cm) was used. Living image software (Caliper Life
Sciences) was used for all image acquisition and data analysis. For
ex vivo imaging of organs mice were perfused using phosphate-
buffered saline containing 15 g.L21 glucose. The organs were then
removed and soaked in D-luciferin for 5–10 minutes before
imaging.
Multi-photon microscopy
It has been reported that exposure of the dura by local
craniotomy impairs brain function [20,21]. The skull was therefore
thinned without removing it, and a two-photon microscope used
to image with high resolution through the remaining bone [22].
This technique also enables imaging of objects immediately
beneath the skull. Excitation light came from a Ti-sapphire
femtosecond laser tunable from 700 to 1050 nm (Chameleon
Ultra II, Coherent, Santa Clara, USA). To extend the wavelength
range, the output of the Ti-S laser passed through an optical
parametric oscillator (OPO, Coherent): when pumped by the Ti-S
laser at about 800 nm, outputs up to 1200 nm were obtained. It
was possible to use part of the pump wavelength (800 nm)
simultaneously with the OPO output. The intensity of the Ti-S
beam bypassing the OPO was regulated by an acousto-optical
modulator controlled by the imaging program (Zen 2010, Zeiss).
The scan head (Zeiss LSM7 MP) had a maximum rate of 8 frames
per sec. Almost all the imaging was done with a 206 water
immersion objective, NA 1.0. (W Plan-Apochromat, Zeiss). The
dichroic mirror in the microscope nose split the beam at a
wavelength of 690 nm except when quantum dots emitting at
705 nm were used, in which case a dichroic splitting at 740 nm
was used. Five detectors of non-descanned fluorescence were
available, three multialkali photodiodes, and two GaAsP detectors.
Image files were analysed, and videos prepared, using Volocity
(Perkin-Elmer).
Surgical preparation
Initial anaesthesia of mice was achieved by a low dose of
Hypnorm/Hypnovel (VetaPharm/Roche 5 ml/kg body weight,
intraperitoneally) and was reinforced as necessary with isoflurane
in oxygen. Core temperature was maintained at 36.8–37.0uC by a
heating mat (De-Icers (MHG) Ltd, Cheltenham, UK). The
parietal skull was exposed and glued to a plate with a hole of
5 mm diameter and the bone within the hole was thinned to about
20 mm [23]. During the thinning and imaging, the skull was
superfused with a Tris-buffered saline containing 2 mM CaCl2.
After imaging, the mouse was humanely killed by an overdose of
anaesthetic.
Exogenous fluorescent labels
Blood plasma was labeled by intravenous injection of dextran
70 kD, 50–70 ml of 100 mg.ml21, conjugated with either fluores-
cein isothiocyanate or rhodamineB isothiocyanate (both Sigma-
Aldrich), or with quantum dots (QTracker, Invitrogen, emission
peak at 705 nm, 20–30 ml). For mice infected with WT or LUC2
trypanosomes, a fluorescent diamidine was injected with the
vascular marker, usually DB75 [2,5-bis(4-aminidinophenyl)furan]
or, occasionally, DB829 (CPD-0801, both provided by Rick
Tidwell, University of North Carolina, Chapel Hill) at a final
concentration of 10 mg/kg body weight.
Counting trypanosomes using multi-photon microscopy
Extravascular trypanosomes in the meninges moved too fast to
be imaged in three dimensions. However, there was a marked
Trypanosome-Brain Interactions
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maximum in the population in a layer less than about 10 mm thick.
To obtain approximate values for the number of trypanosomes per
unit area, areas were chosen at random, and while focused at the
depth of maximum trypanosome population, a time series at the
maximum scan rate for 100 cycles (giving a total time of 12 s) was
acquired. The video was played back at reduced speed and the
trypanosomes counted. The size of the imaged area was chosen to
include fewer than 20 trypanosomes, and was usually 212 mm2 or
143 mm2. At least 8 non-overlapping areas were counted in each
mouse.
Results
Generation of bioluminescent Trypanosoma brucei brucei
To allow in vivo tracking of T. b. brucei over the full course of
infection we generated trypanosomes stably expressing biolumi-
nescent proteins. The optimal reporter vector was determined by
employing the monomorphic T. b. brucei 427 strain, a well-
established laboratory strain that can be genetically modified in
vitro with ease, and induces a high level of infection in mice within
2–3 days. Bloodstream form 427 trypanosomes transfected with
Rluc-pHD309 [15] plasmid, to express Renilla luciferase, or with
the TbR-LUC2 (Figure S1), to express firefly luciferase were
analyzed in vitro and in vivo for sensitivity of detection. The majority
of 427-Rluc clones exhibited high luciferase activity in vitro (,106
relative light units), similar to the bioluminescent 427 lines
generated by Claes et al [15]. While 427-LUC2 showed lower
luciferase activity in vitro (,103–104 relative light units) these
trypanosomes were more readily detected in vivo (Figure S2),
presumably because the emission wavelength was longer [24].
TbR-LUC2 vector was therefore chosen for generation of the
reporter lines to be used in the bioluminescence imaging model.
The infection of mice by T. b. brucei GVR35 is the standard model
for assessing drugs against stage 2 HAT [25,26]. In order to
generate bioluminescent GVR35 trypanosomes the TbR-LUC2
plasmid was transfected into culture-adapted bloodstream form
GVR35 parasites. GVR35-LUC2 clone 3 showed the highest
luciferase activity (,103 relative light units) when tested in vitro
(Figure 1A) and this line was used for further in vitro and in vivo
analyses. To determine the limit of detection, a dilution series of
GVR35-LUC2 cells ranging from 10 to 107 trypanosomes were
imaged by an in vivo imaging system (IVIS) (Figure 1A). Wells
containing 106 GVR35 WT trypanosomes were used to determine
the background bioluminescence. The minimal trypanosome
number reliably detected above background was 56103 parasites
(P=0.015). As seen in Figure 1A, bioluminescence increased with
trypanosome number.
Effect of firefly luciferase expression on GVR35 growth
and virulence
A high level of luciferase expression is advantageous for sensitive
imaging but might lead to alterations in virulence and disease
progression. Bloodstream form GVR35-LUC2 cells were indistin-
guishable from the GVR35 WT parent line with regards to growth
in vitro confirming that the pTbR-LUC2 plasmid had no impact
on proliferation in culture. To confirm parity between WT and
GVR35-LUC2 infections in vivo, brains were analysed at 7, 14, 21
and 28 days post-infection for trypanosome load, as assessed by
real-time quantitative PCR (qPCR) of parasite DNA [27] and
for neuropathology (both described previously in [28] and [29]).
No significant difference in parasite burden was detected between
WT and GVR35-LUC2 at days 14, 21 or 28 post-infection,
although a significant increase in parasite burden was observed at
day 7 with GVR35-LUC2 (Figure 1B). Using a well-established
neuropathology grading scale [29], WT and GVR35-LUC2 lines
produced similar disease scores over the course of the infection.
The results suggest that GVR35-LUC2 infections are comparable
to WT in respect to brain parasite load and the neuropathological
response during the CNS stage of disease.
To ensure that the genetic modification of GVR35 trypano-
somes did not influence their sensitivity to trypanocidal compounds
the inhibitory concentration (IC50) for different trypanocides
against WT and GVR35-LUC2 lines was determined using a
modified Alamar Blue assay (Table 1). There were no significant
differences between WT and GVR-LUC2 in the IC50 values for
the compounds tested (diminazene, DB75, DB829 and melar-
soprol), indicating that LUC2 expression did not influence the
sensitivity to these trypanocides in vitro.
Figure 1. Generation of bioluminescent T. brucei GVR35 for
detection of trypanosomes in vivo. (A) Live GVR35 WT and -LUC2
clones were assessed for luciferase activity in vitro after addition of D-
luciferin. The in vitro detection limit was determined by imaging a
dilution series of GVR35-LUC2 using IVIS. Data show, on a logarithmic
scale, average total flux (in photons per second) 6 SD of replicate wells
containing a specified trypanosome number. The dotted line indicates
background bioluminescence for GVR35 WT. (B) Brains of mice infected
with WT or GVR35-LUC2 were compared for trypanosome DNA and
neuropathology at different times after infection. Real-time qPCR of the
trypanosome TbPFR2 gene was performed on brain homogenates.
Neuropathology was scored on haematoxylin and eosin stained
sections. Graphs show means and 95% confidence interval for each
group (n= 11–12 per group). P value (Student’s t test) compared to
GVR35 WT is indicated *P,0.05; **P,0.01.
doi:10.1371/journal.pntd.0002384.g001
Table 1. In vitro sensitivity of GVR35-LUC2 compared to WT
for different trypanocidal compounds.
IC50 [nM]{
Compound T. bb GVR35 WT T. bb GVR35-LUC2
Diminazene aceturate 412.369.3 431.2624.2
DB75 140.6626.2 140.3629.5
DB829 525.6656.5 506.7650.4
Melarsoprol 15.562.4 16.363.1
{Data show means 6 SD of at least three independent assays with duplicate
wells.
doi:10.1371/journal.pntd.0002384.t001
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Use of bioluminescent GVR35 to monitor disease
We next used GVR35-LUC2 to monitor trypanosome burden
using IVIS through the full course of an infection. Mice developed
fluctuating blood parasitemia [30] and survived up to day 35. Strong
bioluminescence was present by day 7 and the signal increased and
disseminated to the heads as well as other body regions as the
infection progressed (Figure 2). While intermittent decreases in
blood parasitemia were observed, bioluminescence increased over
time, indicating that the extravascular trypanosome population
expands during the course of infection and contributes to the overall
bioluminescence. To confirm that GVR35-LUC2 established a
CNS infection, brains from infected mice were removed, soaked in
D-luciferin and imaged ex vivo. Perfusion of mice prior to removal of
the brain reduced the bioluminescence by ,5-fold compared to
brains from non-perfused mice, indicating that trypanosomes in the
blood serving the brain contribute significantly to total brain
bioluminescence (Figure 3A, bottom panel). Therefore, to limit the
analysis to extravascular trypanosome loads, mice were routinely
perfused before removal of the brains. Imaging over the course of
infection revealed the presence of extravascular bioluminescent
trypanosomes in brains at day 7 with an increase in biolumines-
cence, and thus trypanosome loads, over time (Figure 3A, top panel).
We further examined whether this method could be used to detect
live trypanosomes in other organs. Mice infected for 35 days were
perfused and various organs including brain, spleen, liver, heart,
lungs, inguinal-, axilliary-, brachial-, cervical-, mesenteric- and
popliteal lymph nodes, were removed and imaged after soaking in
D-luciferin (Figure 3B). Bioluminescence was detected in all organs
evaluated, indicating the widespread distribution of trypanosomes at
the late stage of infection, but also the potential use of this method to
evaluate trypanosome burdens in organs during infection.
Assessment of in vivo drug efficacy using the
bioluminescent GVR35 model
To validate bioluminescence imaging as a method for evaluating
the efficacy of trypanocidal compounds, GVR35-LUC2-infected
mice were treated with known trypanocides. We firstly used two
well-established drugs: diminazene aceturate (berenil), a first
stage drug known to be ineffective for stage 2 [25], and
melarsoprol, a drug that clears trypanosomes from the CNS
[19,31]. Mice were imaged at day 21 to confirm that the
infection was established, then treated with the relevant
compound and imaged weekly. In the first 2 weeks after
diminazene treatment most of the bioluminescence detected pre-
treatment disappeared and trypanosomes were undetectable in
the blood (Figures 4A, S3A and S4A). Head images, however,
revealed low bioluminescence, indicative of persistent trypano-
somes. Bioluminescence in the heads increased by day 41 with
possible localisation in the forebrain and cervical lymph nodes,
and spread to the rest of the mouse, and in particular to the
spleen in the following weeks. Trypanosomes became detectable
in the blood 1–3 weeks after bioluminescence detection by IVIS
imaging (Table 2). While bioluminescence was consistently
found in the heads of treated mice, the position of the signal
varied and often appeared to be located in the rostral area early
after treatment. To confirm that trypanosomes did in fact
survive in the brain following treatment mice were perfused and
brains imaged ex vivo (Figure 4Aii). Strong bioluminescence was
observed in in vivo head and ex vivo brain images of untreated
mice at day 21 indicating a high level of infection before
treatment. Head images of the same mice 1 week after
diminazene treatment showed either no signal (mouse nr 3),
signals in the rostral area towards the eyes and nose (mouse nr
4, 5, 6) or signals emanating from the inner ear (mouse nr 5
and 6). Ex vivo brain images from these mice clearly indicated
that bioluminescent trypanosomes were still present in all the
brains after treatment, and were predominantly located in the
olfactory bulb and cerebellum region.
Treatment with melarsoprol led to the loss of all biolumines-
cence within a week (Figures 4B, S3B and S4B) and mice
remained aparasitemic and clear of bioluminescence until the end
of the experiment at day 184. Quantitative PCR analysis of
brains from these mice also showed that they were cleared of
Figure 2. In vivo imaging of bioluminescent T. brucei GVR35 over the course of infection. GVR35 WT or -LUC2-infected mice were imaged
at different times after infection. Total flux in photons per second (p/sec) for the mouse body (ventral view) or head region (dorsal view) is shown. D-
luciferin (150 mg/kg) was injected intraperitoneally 10 minutes before imaging. ND indicates that trypanosomes were not detected in blood samples.
Images show the same two representative mice over the full course of infection. Images of a GVR35 WT-infected mouse are shown to indicate the
background bioluminescence. The colour scale indicates bioluminescent radiance in photons.second21.centimeter22.steradian21.
doi:10.1371/journal.pntd.0002384.g002
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trypanosome DNA. Thus the method reliably reported clearance
of trypanosomes in cured mice and confirmed previous findings
that 3 doses of topical melarsoprol administered during stage 2
disease results in 100% cure rate (Table 2, [19]).
The efficacy of two experimental diamidines was then tested in
the GVR35-LUC2 imaging model. DB75 clears trypanosomes
from blood but is unable to cure mice during stage 2 disease, while
its aza-analog DB829 is effective at curing CNS infections [32,33].
When GVR35-LUC2-infected mice were treated on day 21 post-
infection with the maximum tolerated dose of DB75 (20 mg/kg for
5 days) trypanosomes were cleared from the blood at day 28 but
in vivo bioluminescence was still detected in the heads and tails
(Figures 4C and S3C). By day 36 most of these bioluminescent
signals disappeared but remained at a low level in the heads of
50% of treated mice. Bioluminescence reappeared in the heads of
the remaining mice over the following weeks (Table 2 and Figure
S4C). The bioluminescent signal subsequently increased and
spread: at first located in the front of the head, then in the cervical
lymph nodes and finally the spleen and rest of body (Figure S3C).
Trypanosomes were not detected in the blood until day 85 or later
(Figure 4C and Table 2). In DB75-treated mice a bioluminescent
signal showing the presence of trypanosomes was detected a full 7
weeks before parasites were first detected in blood.
Dose-dependent in vivo activity was observed for DB829 (Table 2
and Figures 4D, S3D, S4D and S5). Treatment with the maximum
tolerated dose for this drug (40 mg/kg for 3 days followed by
20 mg/kg for 1 day) resulted in a 100% cure rate. At day 26
trypanosomes could no longer be detected in the blood of treated
mice (Figures 4D and S3D) but bioluminescence was still visible in
the heads and in the areas of lymph nodes and spleen. Most of this
was abolished by day 41 although residual bioluminescent spots
(,36105 photons/sec) were observed in the heads of some mice.
In the following weeks mice were cleared of all bioluminescence
and no trypanosomes were detected in blood by the endpoints at
day 98 or day 197. Lower doses of DB829 were unable to cure all
mice: 2/6 relapsed after treatment with 25 mg/kg for 2 days
followed by 40 mg/kg for 2 days, 1/6 mice relapsed after
treatment with 25 mg/kg for 5 days (Figure S5) and 3/4
relapses occurred at the lowest dose of 20 mg/kg for 4 days
(Table 2). A comparison between bioluminescent images of mice
that relapsed and those that remained aparasitemic indicated that
bioluminescence of 36105 photons/sec or higher for head regions
reliably predicted relapse. This value offers the means to provide a
quantitative cut-off with a head signal below 36105 photons/sec
defined as negative. For animals treated with sub-curative doses of
DB829 bioluminescence was detected between 3 and 7 weeks
before trypanosomes were identified in the blood (Table 2).
Multi-photon imaging of trypanosome infections in the
brain
Trypanosome infection causes meningitis [34,35] and the
presence of trypanosomes in the meninges, and also the superficial
parenchyma, has been reported [36–38]. If trypanosomes were
present in these locations they would contribute to the in vivo IVIS
signal from the head. Intravital multi-photon microscopy through
the thinned skull allowed the identification of individual intravas-
cular and extravascular parasites in the meninges, and below that
to a depth of about 150 mm into the parenchyma. The presence of
parasite populations in these different regions, and their suscep-
tibility to drug treatments shown by IVIS imaging to be effective
against stage 1 or stage 2 disease, could therefore be assessed.
Intravascular trypanosomes were detected through the thinned
parietal skull to a depth of about 150 mm below the pia mater. In
mice infected for 3 days with T. b. brucei strain 427 expressing
fluorescent mCherry, trypanosomes were visible in blood vessels,
but virtually none were extravascular (Figure 5A and Video S1)
demonstrating that the surgery itself did not give trypanosomes
access to extravascular spaces. Mice were then infected with T. b.
brucei strain GVR35 modified to express mCherry and the
parasites were imaged between days 13 and 41. Motile GVR35
trypanosomes were observed in extravascular spaces in the
meninges. To localize them, we focussed first on the underside
of the skull and then imaged deeper into the meninges. The
trypanosomes tended to be present in a thin layer, and in each
microscope field the depth of greatest trypanosome density was
estimated. The mean depth of this peak density was 28.466.7 mm
(mean 6 SD, n= 8 mice) below the skull (Figure 5B and Video
S2). To compare results of multi-photon imaging with IVIS
imaging it was necessary to use bioluminescent GVR35-LUC2
and WT (as control) trypanosomes. Addition of a fluorescent
stain was required to allow detection of trypanosomes using the
Figure 3. Ex vivo imaging of bioluminescent T. brucei GVR35 over the course of infection. (A) Brains were removed from perfused GVR35-
infected animals at indicated days after infection, soaked in D-luciferin and imaged ex vivo. A comparison between brains from perfused and non-
perfused animals at day 14 is shown at the bottom. (B) Organs were harvested from perfused GVR35 WT or -LUC-infected mice at day 35, soaked in D-
luciferin and imaged ex vivo. Colour scales indicate bioluminescent radiance. In A, different scales are used for weak (a) and stronger (b)
bioluminescent radiance in photons.second21.centimeter22.steradian21.
doi:10.1371/journal.pntd.0002384.g003
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Figure 4. Bioluminescence imaging of T. brucei GVR35-LUC2- infected mice to assess in vivo trypanocidal activity. Mice were treated
with (A) diminazene aceturate ((i) n= 11, (ii) n= 6), (B) melarsoprol (n= 12), (C) DB75 (n= 6) or (D) DB829 (n=8) from day 21 and imaged on indicated
days after infection. D-luciferin (150 mg/kg) was injected intraperitoneally 10 minutes before imaging. Bioluminescence from the heads of mice is
shown as total flux in photons per second (p/sec). ND indicates that trypanosomes were not detected in blood samples. For each treatment images of
the same two representative mice over the entire period are shown. In Aii brains were harvested from perfused GVR35-LUC2-infected mice at day 21
(untreated) or day 35 (diminazene-treated), soaked in luciferin and imaged ex vivo. Corresponding untreated heads and treated heads and brains are
shown. The same two colour scales are used for all treatments for strong (a) and weaker (b) bioluminescent radiance in photons.second21.centi-
meter22.steradian21. The colour scale used is indicated in the top right corner of each image.
doi:10.1371/journal.pntd.0002384.g004
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multi-photon approach and since DB75 accumulates within
circulating trypanosomes and has intrinsic fluorescent properties
[39] this compound could be used to label trypanosomes. We
tested the GVR35 strain and found that, following intravenous
injection of DB75 (10 mg/kg), fluorescence-labeled extravascular
trypanosomes were clearly visible in the meninges. Within 25 min
of DB75 administration, the nucleus and kinetoplast were visible
(Figure 5C inset and Video S3), as were nuclei of host cells in the
meninges (Figure 5, C and D, and Video S4). Trypanosomes could
be unambiguously identified by virtue of their size and motility,
which was not affected by DB75 during the maximum of 3 hours
imaging per mouse. Furthermore, moving, labeled, trypanosomes
were still observed 24 hours after DB75 administration (Figure 5C
and Video S5). By comparing the distributions of trypanosomes
that expressed fluorescent proteins, and those that were labeled by
DB75, we concluded that all the extravascular trypanosomes
imaged by multi-photon microscopy were accessible to this
compound. Trypanosomes were detected in the meninges from
day 5 post-infection with no marked difference in the meningeal
population numbers between GVR35 WT, -LUC2 and -mCherry
(Figure 5E).
To determine the susceptibility of meningeal trypanosomes to
stage 1 drugs, GVR35-infected mice were treated with 40 mg/kg
diminazene [25] at day 21. Moving trypanosomes could not be
detected in the meninges two days after treatment, indicating that
trypanosomes had been cleared from this site (Video S6). Another
group of treated mice were imaged on day 44 (23 days after
treatment) first by IVIS then by multi-photon imaging. Although
no trypanosomes could be detected in the blood of these mice,
IVIS imaging revealed bioluminescence in the brain (Figure 5F).
However, no trypanosomes were observed by multi-photon
microscopy, indicating that IVIS-detected bioluminescence did
not originate from meningeal trypanosomes (Figures 5G and S6).
At later times, trypanosomes of the various lines used were
detected in the meninges but only after their reappearance in the
blood (Figure 5E).
Discussion
Effective treatment of stage 2 HAT requires a drug that crosses
the blood-brain barrier in a concentration sufficient to kill CNS-
resident trypanosomes. Many trypanocidal drugs, such as those
used for stage 1 treatment, clear trypanosomes from the
vasculature and peripheral compartment, but parasites that
remain viable in the brain will eventually re-establish infection
in the blood [11,25,40]. Current pre-clinical mouse models of
stage 2 HAT assess the efficacy of drugs by the detection of
trypanosomes in blood following treatment. In the case of failure,
the re-emergence of blood trypanosomes often occurs several
months after treatment and the standard model requires 180 days
post-treatment follow up to declare a drug curative in stage 2.
Here, we describe an infection model that uses bioluminescence
imaging to detect trypanosomes in the brain following drug
treatment, which is a significant improvement upon the classical
180 day model.
Bioluminescence imaging has been widely used for in vivo
tracking of tumour cells in cancer and the distribution of
pathogens in infected animals [12,14,41–43]. LUC2, a modified
firefly luciferase, has so far provided the best sensitivity for in vivo
detection [44,45] and its substrate luciferin is known to cross the
blood-brain barrier, allowing successful imaging in the brain
[43,46,47]. The gene has been optimized for cytosolic expression
by the removal of a peroxisomal targeting sequence, which is
present at the C-terminal end of the native luciferase gene and
shown to target native luciferase to the glycosomes in T. brucei [48–
50]. We found LUC2 firefly luciferase to be superior to Renilla
luciferase [15,16] for in vivo detection of T. b. brucei, most likely due
to its longer wavelength emission (562 nm) [24]. Crucially for the
success of the model, the expression of LUC2 from the ribosomal
locus in GVR35 remained stable over the course of infection. The
TbR-LUC2 plasmid could also be used for the generation of other
bioluminescent Trypanosoma spp. making it possible to extend the
analysis of promising compounds to tests on field isolates.
Table 2. In vivo antitrypanocidal activity in the GVR35-LUC2 mouse model.
Compound Dose (days administered)a Relapsed/total Day p.i. detected by IVISb Day p.i. detected by microscopy
Melarsoprolc 3.6 mg (3) 0/12 None by d184 None by d184
DB829 40 mg/kg (3) 0/8d None by d197 None by d197
20 mg/kg (1)
DB829 25 mg/kg (2) 2/6 d71 (2) d94 (1), d123 (1)
40 mg/kg (2) rest clear until d182
DB829 25 mg/kg (5) 1/6e d50 (1) d77 (1)
rest clear until d192
DB829 20 mg/kg (4) 3/4 d35 (2), d56 (1) d53 (1)
all euthanised d60
DB75 20 mg/kg (5) 6/6 d36 (3), d57 (1), d64 (1), d85 (1), d98 (4), d106 (1)
d85 (1)
Diminazene aceturate 40 mg/kg (1) 11/11 d28 (4), d35 (1), d41 (2), d49 (4), d56 (5), d62 (2)
d49 (4)
aDoses were administered on consecutive days.
bDay post-infection (p.i.) when positive bioluminescence was first detected is shown with number of mice indicated in brackets. The criterion for positive
bioluminescence was set at total flux of the head image $36105 photons per second.
cMelarsoprol was applied topically to the back of the neck while the other compounds were injected intraperitoneally.
d1/8 mice died 4 days after treatment, possibly due to toxicity.
e1/6 mice was killed on day 44 p.i. due to hind leg paralysis.
doi:10.1371/journal.pntd.0002384.t002
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The GVR35-LUC2 model was validated initially using two
widely used trypanocidal drugs: diminazene aceturate, a veteri-
nary drug that can cure stage 1 but not stage 2 disease [25], and
melarsoprol, a drug used for stage 2 human disease that cures
100% of treated mice when appropriately dosed [19]. As expected,
relapse was observed in the case of diminazene while melarsoprol
cured mice, thus providing a benchmark for compounds that cure
stage 1 and stage 2 disease. In cases of relapse after treatment with
diminazene, bioluminescence was first detected in the heads of
mice before disseminating throughout the body. Surprisingly, early
signals were often located in rostral areas of the heads in in vivo
imaged mice, while ex vivo brain images clearly showed biolumi-
nescence in the brain. It is feasible that in vivo rostral signals are
linked to the strong bioluminescence in olfactory bulbs, and the
inner ear signals to the cerebellum but this hypothesis requires
further investigation. The discrepancy between signal strength
detected by in vivo and ex vivo imaging suggests that much of the
brain bioluminescence is lost during in vivo imaging, as observed by
others [51], or that the substrate D-luciferin does not accumulate
in the brain in sufficient amounts with the 150 mg/kg dose used.
In vivo sensitivity may be improved for future studies with the use
of red-shifted luciferases [52], red-shifted luciferin analogues
[53] or by increasing the D-luciferin dose [54]. The biolumines-
cence detected in ex vivo brains is consistent with previous
observations that trypanosomes survive in the CNS after sub-
curative treatment [11,25] but it does not exclude the possibility
that trypanosomes may survive in other extravascular regions. The
use of GVR35-LUC2 and ex vivo imaging of different tissues early
after treatment should be helpful in identifying areas where
parasites survive.
For further refinement and testing of the model, groups of mice
were treated with two experimental diamidine compounds: DB75,
a compound that failed to cure stage 2 models of disease even
at the highest tolerated dose, and DB829, shown to have dose-
dependent activity against CNS trypanosomes [33]. Importantly,
after DB75 treatment, IVIS imaging rapidly revealed that
trypanosomes remained viable in the head, even though the
blood was cleared. The time taken to identify DB75 as an
unsuccessful stage 2 compound was thus reduced by seven weeks
using our bioluminescence imaging approach compared to the
standard model relying on relapse in the blood.
Although bioluminescence remained visible in some mice within
the first 2 weeks after treatment it disappeared in others to re-
emerge in the following weeks. To distinguish between cured and
non-cured mice it is thus necessary, with the model described here,
to extend the imaging period to 60 days post-treatment.
While all bioluminescent signal was cleared one week after
melarsoprol treatment, bioluminescence remained visible in mice
treated with DB829. This observation may relate to differences
in the in vivo killing rate and distribution of compounds in
extravascular tissues. In vitro, melarsoprol kills trypanosomes more
rapidly than DB829 [55–58]. In addition to providing information
Figure 5. Trypanosomes invade the meninges. (A) Lister 427-mCherry trypanosomes (red) in a meningeal blood vessel (outlined by dashed
blue lines) at day 3 (Video S1). (B) Extravascular GVR35-mCherry trypanosomes (red) day 13. Blood and collagen appear green. A rapidly moving
intravascular trypanosome is indicated by the arrow (Video S2). (C) 24 hr after intravenous (i.v.) injection of DB75 meningeal trypanosomes are
labeled and motile (arrows), as are host nuclei (Video S5), day 28. Inset shows a different mouse at day 10, 25 min after i.v. injection of DB75, only the
nucleus and kinetoplast are labeled (arrow heads, Video S3). (D) At day 25 numerous GVR35-LUC2 trypanosomes (moving dots in Video S4) are
present in the meninges. Labeling by i.v. injection of DB75. (E) Numbers of meningeal trypanosomes plotted against days post-infection. Diminazene
(40 mg/kg) at day 21 cleared the meninges of trypanosomes until about day 58 (crosses). (F) Treatment with diminazene at day 21 reduced luciferase
emission but by day 44 there was strong emission from the head, despite zero blood parasitemia. Scale in photons.second21.centimeter22.ster-
adian21. (G) Subsequent multi-photon imaging in area circled in (F) showed no motile trypanosomes in the meninges. I.v. injection of DB75 labeled
host nuclei. All scale bars 20 mm.
doi:10.1371/journal.pntd.0002384.g005
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about relapse, the in vivo imaging model applied here can therefore
distinguish in vivo between fast-acting compounds, which may be
more favourable, and those with slower activity.
Despite having a higher IC50 value than DB75 in in vitro testing
(Table 1, [33,58]), DB829 was more active against CNS
trypanosomes in vivo. This discrepancy between in vitro and in vivo
efficacy may be explained by different distribution of these two
compounds in vivo. Studies using the prodrug of each compound
have shown higher systemic levels of DB829 compared to DB75
[59] but it is not known whether this accounts for its greater
efficacy in the brain. Differences in the uptake of diamidines by
trypanosomes grown in vitro and in vivo have also been described
[58]. Such observations highlight the need for in vivo assessment of
compounds under development as stage 2 drugs, and extension of
pharmacokinetic studies to assess distribution of drugs in the CNS
and their uptake by resident trypanosomes.
Using multi-photon imaging, which provides optical resolution
of individual parasites, we observed invasion of the meninges as
early as day 5 post-infection [37,38]. These parasites are likely to
be responsible for some of the bioluminescent signal emanating
from the head. However, clearance by diminazene indicates that
this population is not protected by the blood-brain barrier, and
does not significantly contribute to bioluminescent signals ema-
nating from the head following chemotherapy. The meningeal
trypanosomes are thus not responsible for the later relapse
observed in mice treated with stage 1 drugs. These findings
extend our understanding of CNS-associated trypanosomes to
include populations that enter the CNS during earlier stages of the
infection and are accessible to stage 1 drugs.
Trypanosomes in the superficial meninges of mice may be
equivalent to the so-called ‘intermediate stage’ of infection in some
patients with HAT. This intermediate stage of infection has been
suggested following successful treatment of patients presenting
with raised CSF white blood cell counts with stage 1 drugs [60–
62], though the concept and treatment of this clinical scenario
remains controversial. The multi-photon imaging approach used
in this study revealed a location in the brain where trypanosomes
are accessible to stage 1 drugs, but we were unable to identify
parasites within parenchyma beyond the blood-brain barrier,
protected from stage 1 treatments, that were responsible for the
eventual recrudescence of parasitaemia. Further investigations,
utilising this powerful technique, will provide invaluable informa-
tion about trypanosome interactions and distribution throughout
the brain. For example with the use of fine optical probes such as
gradient index (GRIN) lenses the range of multiphoton imaging
could be extended to reach several millimetres into the brain
[63,64].
In summary, we have developed in vivo bioluminescence
imaging to extend the capability of the currently employed T.
brucei strain GVR35 model of stage 2 disease. The model provides
a substantial improvement in time taken to establish whether a
compound is curative in stage 2 disease. The time taken to assess
drug efficacy in stage 2 trypanosomiasis has been a major bottle
neck in the drug development process and the profound reduction
in screening time we present here, cutting the post-treatment
follow up time by two thirds, represents a significant advance that
should expedite drug discovery for stage 2 HAT.
Supporting Information
Figure S1 Vector map of the TbR-LUC2 plasmid.
Expression of firefly luciferase (LUC2) is under the control of an
rDNA promoter with a GPEET 59UTR and ab Tubulin 39UTR.
The plasmid contains a puromycin resistance cassette with a ab
Tubulin 39UTR to allow for the antibiotic selection of trypano-
somes that integrate the construct. An rDNA spacer was added at
the 39end enabling integration of SacI-KpnI linearized plasmid into
the rDNA loci of trypanosomes. The size of each DNA fragment in
kilobase (kb) is indicated as well as the restriction sites used for
cloning.
(TIFF)
Figure S2 Generation of bioluminescent T. brucei 427 to
determine the optimal reporter for in vivo imaging. (A)
Live T. b. 427 expressing Rluc or LUC2 were assessed for
luciferase activity in vitro after addition of appropriate substrates.
(B) Mice infected with 427 WT, 427-Rluc (clone 3) or 427-LUC2
(clone 4) were imaged by IVIS after intraperitoneal administration
of D-luciferin (LUC2) or intravenous administration of coelenter-
azine (RLuc). Total flux in photons per second (p/sec) shows
bioluminescence over the mouse body. ND indicates that
trypanosomes were not detected in blood samples. Representative
images of individual mice within each group are shown (n=3).
The colour scale indicates bioluminescent radiance in photo-
ns.second21.centimeter22.steradian21.
(TIFF)
Figure S3 Bioluminescence imaging of GVR35-LUC2-
infected mice to assess in vivo trypanocidal activity.
Mice were treated with (A) diminazene aceturate (n=11), (B)
melarsoprol (n=12), (C) DB75 (n=6) or (D) DB829 (n=8) from
day 21 post-infection (see Materials and Methods for dosing
regimens) and imaged weekly after drug administration. Biolumi-
nescence from the bodies or heads of infected mice following
injection of D-luciferin (150 mg/kg) is shown as total flux in
photons per second (p/sec). ND indicates that trypanosomes were
not detected in blood samples. For each treatment images of the
same two representative mice over the entire period are shown.
The same two colour scales are used for all treatments to indicate
strong (a) and weaker (b) bioluminescent radiance in photons.se-
cond21.centimeter22.steradian21. The colour scale used is
indicated in the top right corner of each image.
(TIFF)
Figure S4 Bioluminescence over time in GVR35-LUC2-
infected mice to assess in vivo trypanocidal activity.
Mice were treated with (A) diminazene aceturate (n=11), (B)
melarsoprol (n=12), (C) DB75 (n=6) or (D) DB829 (n=8) from
day 21 post-infection (see Materials and Methods for dosing
regimens) and imaged weekly after drug administration. Plots
show total flux in photons per second for whole bodies (left) and
heads (right) of all mice in each treatment group. The time of the
bioluminescence measurement in days post-infection is shown on
the x-axis.
(TIFF)
Figure S5 Bioluminescence imaging of GVR35-LUC2-
infected mice to assess in vivo trypanocidal activity of
DB829. Mice were treated with 25 mg/kg of DB829 for 5
consecutive days from day 21 post-infection (p.i.) and imaged
weekly after injection of D-luciferin (150 mg/kg). Bioluminescence
from the bodies or heads of infected mice is shown as total flux in
photons per second (p/sec). ND indicates that trypanosomes were
not detected in blood samples. Images of the same two
representative mice over the entire period are shown. For day
113 and 192 p.i. only one mouse is shown because the relapsed
mouse was euthanised. Different scales are used for strong (a) and
weaker (b) bioluminescent radiance in photons.second21.centime-
ter22.steradian21.
(TIFF)
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Figure S6 Trypanosomes in the meninges contribute
little to the IVIS signal. The mean luciferase radiance from
an area over the parietal skull that approximated the area
subsequently imaged by two-photon microscopy was measured
(see Figure 5E). Trypanosomes were rendered fluorescent by i.v.
injection of DB75 and imaged through the thinned skull (as for
Video S3). Approximate mean numbers per unit area of meninges
were calculated for each mouse by counting extravascular
trypanosomes in videos from 8–10 randomly selected fields of
view. In each field, the imaging plane was set so that the greatest
number of trypanosomes was observed, and all trypanosomes that
appeared during 12 s of imaging were counted. This method will
have systematic errors, but, in general, the trypanosomes were
confined to a range of depths sufficiently small that during the 12 s
of imaging nearly all the trypanosomes moved into the imaging
plane and were detected.
(TIFF)
Table S1 Primer sequences used to amplify the rDNA
promoter, spacer, UTR fragments and reporter genes
(the incorporated restriction sites are underlined).
(DOC)
Video S1 Intravascular T. brucei 427-mCherry trypano-
somes. 3 days p.i. Blood marker dextran-fluorescein, 70 kD. Real
time. Excitation wavelength 1050 nm. The width of the frame is
68 microns.
(MOV)
Video S2 Extravascular T. brucei GVR35-mCherry
trypanosomes in the superficial meninges. 13 days p.i.
Collagen fibres of the dura are revealed by second harmonic
generation (green). Approximate real time. Width of frame
424 microns.
(MOV)
Video S3 Intravascular DB75 (10 mg/kg) labels nuclei
and kinetoplasts of extravascular trypanosomes in the
meninges. Excitation wavelength 750 nm. Width of frame
121 microns.
(MOV)
Video S4 Luciferase-expressing trypanosomes at 25
days p.i. Trypanosomes fluorescence labeled by i.v. injection of
DB75. Width of frame 424 microns.
(MOV)
Video S5 DB75 does not abolish movement of extravas-
cular trypanosomes 24 h after i.v. injection. Z projection
of a stack 5 microns deep. Occasional trypanosomes appear with
emission from the whole body extending into the green, and there
are stationary green objects which may be debris. Excitation
wavelength 800 nm. Blood marker dextran-rhodamine. Width of
frame 105 microns.
(MOV)
Video S6 A companion mouse to that of Video S5 was
treated with diminazene (40 mg/kg) at 21 days p.i. and
imaged at 44 days p.i. No trypanosomes are detected as
moving spots. Approximate real time. Width of frame 424 mi-
crons.
(MOV)
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